Morphic Holding, Inc. Profile Avatar - Palmy Investing

Morphic Holding, Inc.

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF…
Biotechnology
US, Waltham [HQ]
MORF/Financials
Wall Street · Earnings · Institutional Sentiment

Analysts

Earnings
Reported
Past Estimate Consensus
Future Estimate Consensus
EPS Revenue EBITDA EBIT SGA
FY EPS Revenue [mil.] Profit [mil.] EBITDA [mil.] EBIT [mil.] Expenses · SGA [mil.]
E E E E E E
All monetary values are presented in USD ($). E stands for Estimate.
2019 - -2.948 - 22 - -124 - -22 - -22 - 353
2020 -1.4400 -1.336 16 45 -43 -56 -46 -44 -100 -44 10 707
2021 -1.4700 -2.578 44 22 -44 -79 -47 -78 -120 -79 18 349
2022 -2.6300 -1.792 19 67 -94 -4 -95 0.79 -96 -5 27 41
2023 -1.5500 -3.465 70 0.50 -59 -179 -63 0.49 -64 -5 32 7
2024 -3.5900 -3.557 0.52 0.67 -152 -150 -177 0.65 -179 0.65 38 10
2025 - -3.567 - 2 - -150 - -1 - -1 - 30
2026 - -3.760 - 2 - 2.F7X - 2.F71 - 2.F711 - 2.F711
2027 - -4.110 - 2 - 1.F8X - 1.F81 - 1.F811 - 1.F811
2028 - -3.660 - 127 - 0.F9X - 0.F91 - 0.F911 - 0.F911
Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Overall Consensus
Grading Consensus
Morphic Holding, Inc. can't present the grade consensus distribution right now.
Price Target Consensus
Price Then
$n/a
Price Target
$n/a
Price Now
$56.99